Table 1 Patient baseline characteristics and RNA Integrity Numbers (RIN) of myocardial left ventricular RNA samples according to subgroups

Age (years)

68.6 ± 1.9

36.6 ± 4.4

46.8 ± 3.4

58.7 ± 1.4

57.0 ± 1.4

47.7 ± 4.1

59.0 ± 1.6

60.1 ± 1.6

Sex (F, %)

8/9 (89%)

4/7 (57%)

2/12 (17%)

5/12 (36%)

3/11 (27%)

3/9 (33%)

0/9 (0%)

2/9 (22%)

BMI (kg/m²)

26.1 ± 1.6

25.5 ± 1.9

25.7 ± 1.6

26.5 ± 0.8

27.9 ± 0.9

23.5 ± 1.0

27.7 ± 1.6

30.0 ± 1.1

LVEDD (mm)

53.2 ± 4.0

50.7 ± 4.6

73.4 ± 2.6

69.9 ± 2.7

63.9 ± 2.7

76.2 ± 3.8

70.6 ± 6.2

70.0 ± 3.6

EF (%)

61.2 ± 3.4

36.9 ± 4.6

21.9 ± 1.1

27.3 ± 1.4

22.9 ± 1.9

19.3 ± 2.7

19.7 ± 2.4

23.3 ± 2.4

FS (%)

32.1 ± 3.8

20.7 ± 3.5

10.9 ± 0.9

14.6 ± 1.6

13.0 ± 2.5

8.2 ± 2.5

14.7 ± 3.7

15.5 ± 1.4

Years with CRT

–

–

–

–

–

2.9 ± 0.6

3.2 ± 1.8

3.4 ± 0.8

BB

8/9 (89%)

5/7 (71%)

9/12 (75%)

11/14 (79%)

4/11 (36%)

2/9 (22%)

8/9 (89%)

8/9 (89%)

ACEi or ARB

1/9 (11%)

0/7 (0%)

7/12 (58%)

11/14 (79%)

9/11 (82%)

3/9 (33%)

7/9 (78%)

8/9 (89%)

MRA

2/9 (22%)

4/7 (57%)

9/12 (75%)

13/14 (89%)

8/11 (73%)

6/9 (67%)

8/9 (89%)

6/9 (67%)

Diuretic

4/9 (44%)

4/7 (57%)

10/12 (83%)

11/14 (79%)

7/11 (64%)

7/9 (78%)

7/9 (78%)

6/9 (67%)

Statin

3/9 (33%)

0/7 (0%)

2/12 (17%)

7/14 (50%)

6/11 (55%)

0/9 (0%)

4/9 (44%)

8/9 (89%)

SU

–

–

–

–

2/11 (18%)

–

–

2/9 (22%)

Metformin

–

–

–

–

6/11 (55%)

–

–

5/9 (55%)

DPP4i

–

–

–

–

4/11 (36%)

–

–

1/9 (11%)

Insulin

–

–

–

–

3/11 (27%)

–

–

1/9 (11%)

RIN

9.3 ± 0.1

8.3 ± 0.4

8.4 ± 0.3

8.1 ± 0.4

8.2 ± 0.3

7.9 ± 0.3

8.0 ± 0.3

7.9 ± 0.3